Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C

Table 1 Demographic and clinical features of study patients

Variables	Group A (n = 22)	Group-B (n = 14)	P
Age (yr)	35.2 ± 12.1	37.1 ± 14.6	0.629
Male (%)	12 (54.5)	10 (71.4)	0.448
BMI (kg/m2)	25.6 ± 3.3	26.1 ± 3.9	0.78
ALT (IU/L)-Range	59.2 ± 22.4-(33-109)	44.8 ± 20.9-(21-71)	0.489
Viral load (x 105 copy/mL)	7.9 ± 4.8	8.1 ± 4.5	0.89
Genotype 1b (%)	86.4	92.9	0.56
HD duration (mo)	52.4 ± 24.7	49.8 ± 21.1	0.95

Table 2 Virological response rates

	Group A (n = 22)	Group-B (n = 14)	P
Early response
Virological (%)	82.4	0	< 0.001
End-of-treatment response
Virological (%)	82.4	0	< 0.001
Sustained response
Virological (%)	64.7	0	< 0.001